Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Crinetics Pharmaceuticals Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Hormonal diseases [C19]

Trial duration

5 Aug 2021 → 5 Mar 2026

Decision date (initial)

2024-09-13

Transition trial

Yes

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

Funding sources

Crinetics Pharmaceuticals, Inc.

External identifiers

EU CT number

2024-511925-71-00

EudraCT number

2020-005431-70

ClinicalTrials.gov

NCT04837040

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Pharmacogenetic, Pharmacokinetic, Pharmacodynamic, Safety

To evaluate the effect of paltusotine versus placebo on IGF-1 response

Secondary objectives 3

1. To evaluate the effect of paltusotine versus placebo on IGF-1 level
2. To evaluate the effect of paltusotine versus placebo on GH response
3. To evaluate the effect of paltusotine versus placebo on acromegaly symptoms.

Conditions and MedDRA coding

Acromegaly

Regulatory references

Scientific advice from competent authorities

European Medicines Agency

EMA paediatric investigation plan (PIP)

EMEA-002682-PIP01-19

Plan to share IPD

No

IPD plan description

Not applicable

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. 01. Willing and able to provide written informed consent prior to any study-related procedures.
2. 02. Willing and able to comply with the study procedures as specified in the protocol and comply with the study treatment administration.
3. 03. Adults ≥18 years of age with medically stable, confirmed-active acromegaly and on an approved, stable monotherapy dose of long-acting octreotide or lanreotide, for at least 12 weeks prior to Screening*. Continuous treatment with octreotide or lanreotide must be at least 24 weeks prior to Screening. *The following prior treatment regimens are allowed for inclusion into this study: long-acting octreotide: 10, 20, 30, 40 mg every 4 weeks or long-acting lanreotide: 60, 90, 120 mg every 4 weeks or 120 mg every 6 or 8 weeks.
4. 04. Previous diagnosis of acromegaly confirmed by the Investigator and approved by the Medical Monitor. This requires evaluable documentation of a pituitary tumor diagnosed by pituitary imaging or histopathologic confirmation of a pituitary adenoma at least 24 weeks prior to Screening. For subjects who have had pituitary surgery, there must be documentation of IGF-1 concentration ≥1.3×ULN at least 12 weeks after last pituitary surgery. The surgery must have been performed ≥24 weeks prior to Screening. Subjects who have not had pituitary surgery must have documentation of IGF-1 concentration ≥1.3×ULN performed ≥24 weeks prior to Screening.
5. 05. Screening average IGF-1 levels of ≤1.0×ULN. The upper limit for eligibility is mean IGF-1 of 1.04 (rounded to 2 decimal places) and will be based on 2 or 3 separate measurements in consultation with the Medical Monitor.
6. 06. Willing and able to undergo biliary/gallbladder ultrasound procedure and pituitary MRI during Screening and during the study.
7. 07. If currently using thyroid hormone therapy, the subject should be adequately treated based on clinical status and free thyroxine concentration measured during Screening and on a stable dose of thyroid hormone for at least 8 weeks prior to Screening.
8. 08. Females who engage in heterosexual intercourse must be of non-childbearing potential, defined as either surgically sterile (i.e., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), OR be postmenopausal with at least 1 year of amenorrhea, OR must agree to use either a highly effective or a clinically acceptable method of contraception from the beginning of Screening until at least 30 days after the last dose of study drug.
9. 09. If the subject is male, the subject should agree to use a condom when sexually active with a female partner of childbearing potential from Screening until at least 30 days after the last dose of study drug (or be surgically sterile [i.e., vasectomy with documentation]; or remain abstinent [when this is in line with the preferred and usual lifestyle]. Male subjects should also agree to not donate sperm for the duration of the study and until at least 30 days after the last dose of study drug.

Exclusion criteria 28

1. 01. Treatment-naïve or treatment-withdrawn acromegaly subjects.
2. 10. Active malignant disease within the last 5 years with exception of basal and squamous cell carcinoma of the skin with complete local excision and resected carcinoma in situ of cervix.
3. 11. Concomitant mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study, and/or evidence of poor compliance with medical instructions.
4. 02. History of pituitary radiation therapy.
5. 03. Subjects with adrenal insufficiency, diabetes insipidus, or central hypogonadism who are not receiving adequate hormone replacement therapy at the time of Screening, as determined by the Investigator.
6. 04. High risk pituitary tumor pattern as defined by:  Compression of the optic chiasm or invasion of adjacent brain structures (other than sphenoid sinus or cavernous sinus)  History of tumor growth within 1 year after surgery or radiation (unless it occurred during a period of medical therapy interruption)  Anticipated requirement for neurosurgical intervention or radiation therapy within the time course of the study.  Pituitary carcinoma currently or at any time in the past.
7. 05. History of major surgery/surgical therapy for any cause within 4 weeks prior to Screening.
8. 06. Diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry, or with change in total daily insulin dose by >15% within 6 weeks prior to Screening.
9. 07. History of unstable angina or acute myocardial infarction within the 12 weeks preceding the screening visit or other clinically significant cardiac disease at the time of screening as judged by the Investigator.
10. 08. Known history of hepatitis B or human immunodeficiency virus, or active hepatitis C infection
11. 09. Known history of, or current alcohol or drug abuse, within the last year.
12. 12. Use of the following medications as outlined:  Pasireotide LAR (within 24 weeks prior to Screening),  Pegvisomant (within 12 weeks before Screening),  Dopamine agonists (within 12 weeks before Screening), or  Short acting somatostatin analogs (SA-SSAs) within last 12 weeks before the first dose of study drug. Note: Withdrawal of these medications should be part of the subject’s medical care plan prior to Screening; entry into the study should not be the sole reason for withdrawal of a prior medication.
13. 13. Current use of oral estrogen replacement therapy for <12 weeks prior to Screening.
14. 14. Current use of medications that are strong inducers of CYP3A4 within 2 weeks prior to Screening
15. 15. Known allergy or hypersensitivity to any of the test materials or related compounds.
16. 16. Active COVID-19 confirmed or suspected based on clinical symptoms.
17. 17. Symptomatic cholelithiasis.
18. 18. Clinically significant concomitant disease including but not limited to cardiovascular disease, moderate or severe renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73 m2), or significant liver disease (including cirrhosis).
19. 19. Clinically significant abnormal findings during the Screening Period or any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject’s safety or ability to complete the study.
20. 20. Systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg during Screening. If the initial measurement is out of range, it may be repeated 2 more times after 15 minutes and the last assessment should be used to determine subject’s eligibility.
21. 21. Resting (at least 10 minutes) palpated pulse rate <45 bpm or >105 bpm during Screening. If either of these criteria is met, the assessment should be repeated 2 more times and the last assessment should be used to determine the subject’s eligibility.
22. 22. QT interval corrected using Fridericia’s formula (QTcF) >480 msec (or corrected QT [QTc] interval >500 msec in the presence of complete bundle branch block) or PR interval >240 msec during Screening based on a central reading of an average of 3 ECGs each separated in time by approximately 1 minute after the subject has rested quietly in the supine position for at least 10 minutes without significant stimulation (noise, television, etc.).
23. 23. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >3×ULN and/or total bilirubin >1.5×ULN during Screening. Subjects with previously diagnosed Gilbert’s syndrome not accompanied by other hepatobiliary disorders and associated with total bilirubin <3.5 mg/dL (<51.3 µmol/L) will be permitted.
24. 24. Poorly controlled diabetes mellitus defined as having a hemoglobin A1c (HbA1c) ≥8.5% (≥ 69 mmol/mol), or estimated HbA1c based on fructosamine if HbA1c is not evaluable (e.g., due to hemoglobinopathies).
25. 25. Female subjects who are pregnant or lactating. Subjects must have a negative pregnancy test during Screening and prior to the first dose of study drug.
26. 26. An employee or immediate family member of an employee of Crinetics.
27. 27. Participation in any previous clinical study with paltusotine.
28. 28. Subjects who have received an investigational drug (either approved or not approved) in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Proportion of subjects who maintain biochemical response in IGF-1 (≤1.0×the upper limit of normal [ULN]) at the End of the Randomized Control Phase (EOR)

Secondary endpoints 3

1. Change from baseline in IGF-1, in units of ULN, to EOR
2. Proportion of subjects with GH <1.0 ng/mL at Week 34, out of those who had GH <1.0 ng/mL at baseline
3. Change from baseline in Total Acromegaly Symptoms Diary (ASD) score to EOR

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Crinetics Pharmaceuticals Inc.

Sponsor organisation

Crinetics Pharmaceuticals Inc.

Address

6055 Lusk Boulevard

City

San Diego

Postcode

92121-2700

Country

United States

Scientific contact point

Organisation

Crinetics Pharmaceuticals Inc.

Contact name

Clinical Medical Lead

Public contact point

Organisation

Crinetics Pharmaceuticals Inc.

Contact name

Clinical Medical Lead

Third parties 8

Locations

6 EU/EEA countries · 10 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 81 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

6 submissions — initial application plus substantial / non-substantial modifications